
David J. Portman
Advertisement
Articles by David J. Portman



16 Open-Label, Randomized, Multicenter, Phase 3, ELAINE 3 Study of the Efficacy and Safety of Lasofoxifene Plus Abemaciclib for Treating ER+/HER2–, Locally Advanced or Metastatic Breast Cancer With an ESR1 Mutation
ByMatthew P. Goetz, MD,Seth A. Wander,Thomas Bachelot,Gerald Batist,Javier Cortés, MD,Massimo Cristofanilli, MD,Giuseppe Curigliano,Alexandre de Nonneville,Einav Nili Gal-Yam,Komal Jhaveri,Cynthia X. Ma, MD, PhD,Heather A. Parsons, MD, MPH,Hope S. Rugo, MD,Sarah L. Sammons,Daniel G. Stover,Chris Twelves, MD, FRCP,Aditya Bardia, MD, MPH, FASCO,Paul V. Plourde,David J. Portman,Senthil Damodaran

Advertisement
Latest Updated Articles
Advertisement
Advertisement
Trending on CancerNetwork
1
FDA Approves RP1/Nivolumab for Progression on Anti–PD-1 Therapy in Melanoma
2
Developers Initiate Phase 2/3 Ivonescimab/EV Trial in Bladder Cancer
3
The Lowest-Ever Hazard Ratio in Multiple Myeloma Bispecific Trials?
4
Invasive Lobular Carcinoma: Diagnosis, Trials and What's Changing
5
